Cytodyn Inc (CYDY)

[$5.95akadawson-m]

Small summary from the Brasil study:

Brasil medical study:

As Brasil has the most death toll in South America, this could be the next country to take action with Leronlimab to fight Covid-19.

Excerpt:
As shown in Table 3, a multiplicity of immunosuppressive drugs or
therapies have been used to reverse the cytokine release syndrome in Covid-19 trials. The tested immunomodulating and/or anti-inflammatory drugs cover a broad range of compounds and modes of action such as classical glucocorticoids or agonists of glucocorticoid receptor (dexamethasone, methylprednisolone, budesonide), biologicals including some of the newest ones (anti-IL-6 monoclonal antibodies tocilizumab and siltuximab, the antibody against CCR5 receptors on T-lymphocytes leronlimab , and an antibody against cytokine fusion protein CD24Fc), ruxolitinib (Janus kinase JAK1 and JAK2 selective inhibitor and blocker of cytokine signalling)

Table 3:
Leronlimab (PRO 140)
Antibody against chemokine CCR5 receptor on T-lymphocytes. Used to treat HIV infections
Severe or critical Covid-19 patients Q (n = 75, n = 390)